Compare Abeona Therapeutics Inc (ABEO) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Abrdn Physical Platinum Shares ETF — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Abrdn Physical Platinum Shares ETF trades at $15.9. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | PPLT | |
|---|---|---|
Market Cap | $424.33M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.45 | $25.23 |
52-Week Low | $4.17 | $11.95 |
Enterprise Value | $279.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
PPLT trades at $15.85, up 1.15% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The stock is set for a 1:10 stock split effective May 18, 2026. Recent news highlights platinum's underperformance versus gold and silver, positioning PPLT as a potential catch-up trade in the precious metals sector.
The outlook for PPLT hinges on a potential rebound in platinum prices, supported by positive sentiment from recent geopolitical developments. Key risks include continued commodity price volatility and the ETF's lack of dividend income, which may deter yield-seeking investors despite its strong past performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
